针对SARS-CoV-2和ACE 2 的人源抗体

twistbioscience 针对SARS-CoV-2和ACE 2 的人源抗体

 

 

 

近的研究表明,SARS-CoV-2中的几种S1和ACE2抗体能够通过在体外与各自的靶点结合,阻断或抑制S1蛋白与ACE2蛋白的结合。

现已上市!  22种针对SARS-CoV-2 S1或人类ACE2蛋白的特异性抗体。

  • 抗SARS-CoV-2刺突蛋白抗体–可用于治疗和诊断应用中的病毒中和或检测。
  • ACE2抗体–具有作为阻断或竞争性抗体用于治疗的潜力。

SARS-CoV-2刺突蛋白抗体和ACE2抗体是由独立的重组人抗体克隆组成,这些新发现的抗体显示出非常高的靶点特异性与亲和力,许多抗体的亲和力系数在皮摩尔到纳米摩尔范围内。

 

克隆基因的新功能

我们通过增加其他质粒制备大小和其他选项(包括标准化,无内毒素的DNA)以及各种试管和平板选项来增强我们的克隆基因产品,以满足您的研究需求。

规模绩效

我们基于硅的高精度DNA合成平台可产生更高质量的基因,并显着提高产量和可扩展性。

我们提供克隆基因和基因片段,以满足您的研究需求:
克隆基因是将合成的DNA克隆到质粒载体中,并验证了NGS序列。
基因片段是线性合成的DNA序列,用于直接克隆或更大的基因组装。

Twist的基因产品为您提供了以所需方式灵活获取所需DNA的灵活性。考虑更大,扩大您的设计范围,并加速发现。
 

 

扭曲基因行动

在大流行保护平台计划中了解科学家如何使用Twist基因,这是一个加速的
抗体开发过程,旨在
在60天内提供治疗途径。

 

 

Twist抗SARS-CoV-2 S1抗体

Twist Biopharma的靶向SARS-CoV-2 Spike蛋白的人类抗体具有潜在的双重用途,可以开发用于病毒中和或分别在治疗和诊断应用中检测。

抗体克隆与SARS-CoV-2 S1单体和三聚体的结合曲线
 

结合SARS-CoV-2 Spike糖蛋白S1或S1三聚体蛋白的单个抗体克隆的亲和力数据。每个克隆都以不同的颜色表示(请参见图例)。

 

 

竞争分析
 

在基于细胞的S1-ACE2竞争试验中测试了S1抗体,以确定它们是否具有阻断标记的S1蛋白与表达ACE2受体的细胞结合的能力。如下图所示,几种抗体可阻止标记的S1 RBD与Vero细胞上的ACE2结合:TB182-03,TB182-04,TB182-06,TB182-13和TB181-63

有关更多信息,请查阅各个抗体或抗体组数据表。

 

规格书

寄主物种人的

物种反应性与冠状病毒SARS-CoV-2发生反应

平移抗原重组片段SARS-CoV-2 S1糖蛋白

数据库链接MN908947.3

克隆性重组单克隆

同型抗体是人类IgG1

纯度CE-SDS大于95%

印版格式体积20 µL /孔,浓度1 mg / mL

管格式体积100μL/管,浓度1 mg / mL

产品SKUS

面板

SKU 102895 $ 12,500

TB181-13 SKU 103103 $ 1,000
TB181-03 SKU 103104 $ 1,000
TB181-04 SKU 103105 $ 1,000
TB181-08 SKU 103106 $ 1,000
TB181-63 SKU 103107 $ 1,000
TB182-13 SKU 103108 $ 1,000
TB182-03 SKU 103109 $ 1,000
TB182-04 SKU 103110 $ 1,000
TB182-06 SKU 103111 $ 1,000
TB182-07 SKU 103112 $ 1,000

Twist Human抗ACE2抗体

人抗ACE2受体抗体对ACE2受体表现出高亲和力,表明它们有潜力被开发为用于治疗应用的封闭抗体或竞争性抗体。

动力学数据
 

抗ACE2抗体对它们的抗原靶标表现出很高的特异性和亲和力,亲和力在皮摩尔至纳摩尔范围内。下表列出了此测定法中的Fc捕获和直接捕获(DC)数据。

 

细胞结合数据
 

整个面板显示了与VERO E6细胞的特异性结合程度,如下表所示,并且还显示了单个克隆的流式细胞仪数据示例。添加S1 Fc融合蛋白和S1 RBD Fc融合蛋白(内部表达)作为ACE2结合的阳性对照。

 

竞争分析
 

为了评估每个抗体克隆干扰S1蛋白与ACE2结合的能力,将ACE2的系列稀释液添加到生物素化的ACE2蛋白中。然后将混合物加入固定在ELISA板上的SARS-CoV-2 S蛋白RBD中,并用抗生蛋白链菌素-HRP检测。在对数转换和曲线拟合之前,从数据点中减去背景。表中列出了所有抗体克隆的IC50值。

有关更多信息,请查看各个抗体或抗体组数据表。
 

规格书

描述识别人ACE2的单个抗体克隆

寄主物种人的

物种反应性与人类ACE2反应

平移抗原重组片段人ACE2 ECD

基因编号59272

数据库NM_001371415

克隆性重组单克隆

同型IgG抗体是IgG2和VHH Fc抗体是IgG1

纯度CE-SDS大于95%

印版格式体积20 µL /孔,浓度1 mg / mL

管格式体积100μL/管,浓度1 mg / mL

产品SKUS

面板

SKU 102896 $ 12,500

TB183-03 SKU 103091 $ 1,000
TB183-05 SKU 103092 $ 1,000
TB183-06 SKU 103093 $ 1,000
TB183-08 SKU 103094 $ 1,000
TB184-111 SKU 103095 $ 1,000
TB184-130 SKU 103096 $ 1,000
TB184-02 SKU 103097 $ 1,000
TB184-04 SKU 103098 $ 1,000
TB184-05 SKU 103099 $ 1,000
TB184-54 SKU 103100 $ 1,000
TB184-07 SKU 103101 $ 1,000
TB184-91 SKU 103102 $ 1,000

 

重组SARS-COV-2刺突RBD蛋白(Delta B.1.617.2) His标签

重组SARS-COV-2刺突RBD蛋白(Delta B.1.617.2) His标签

产品说明书

FAQ

COA

已发表文献

 

Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) . The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 . The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). First detected in India in December 2020, the B.1.617.2, or Delta variant, is considered a Variant of Concern (VOC) as it contains several mutations in the RBD domain that potentially affect viral fitness and transmissibility: L452R and T478K.   

 

产品性质

别名

S protein RBD; S glycoprotein RBD; Spike protein RBD

Accession

QHD43416.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike RBD (Delta B.1.617.2) Protein is expressed from Expi293 with His tag at the C-terminal. It contains Arg319-Phe541(L452R, T478K). 

分子量

Approximately 26.26 kDa. Due to glycosylation, the protein migrates to 35-40 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

活性

ELISA DataImmobilized SARS-CoV-2 Spike RBD (Delta B.1.617.2) , His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

冰袋运输。-20 保存,一年有效期。

复溶后,-20 °C,在未开封状态下保存 3-6 个月。复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装冻存,避免反复冻融。

 

注意事项

1.避免反复冻融。

2.为了您的安全和健康,请穿实验服并戴一次性手套操作。

3.本产品仅作科研用途!

HB221112

重组SARS-COV-2刺突RBD蛋白(Delta B.1.617.2) His标签

暂无内容

重组SARS-COV-2刺突RBD蛋白(Delta B.1.617.2) His标签

暂无内容

 

Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) . The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 . The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). First detected in India in December 2020, the B.1.617.2, or Delta variant, is considered a Variant of Concern (VOC) as it contains several mutations in the RBD domain that potentially affect viral fitness and transmissibility: L452R and T478K.   

 

产品性质

别名

S protein RBD; S glycoprotein RBD; Spike protein RBD

Accession

QHD43416.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike RBD (Delta B.1.617.2) Protein is expressed from Expi293 with His tag at the C-terminal. It contains Arg319-Phe541(L452R, T478K). 

分子量

Approximately 26.26 kDa. Due to glycosylation, the protein migrates to 35-40 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

活性

ELISA DataImmobilized SARS-CoV-2 Spike RBD (Delta B.1.617.2) , His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

冰袋运输。-20 保存,一年有效期。

复溶后,-20 °C,在未开封状态下保存 3-6 个月。复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装冻存,避免反复冻融。

 

注意事项

1.避免反复冻融。

2.为了您的安全和健康,请穿实验服并戴一次性手套操作。

3.本产品仅作科研用途!

HB221112

重组SARS-COV-2刺突RBD蛋白(Delta B.1.617.2) His标签

暂无内容

重组SARS-COV-2刺突RBD蛋白(Delta B.1.617.2) His标签

暂无内容

Abbexa SARS-CoV-2抗原快速检测试剂盒简介

Abbexa SARS-CoV-2抗原快速检测试剂盒简介
我们还提供专业使用的cov-19抗原检测试剂盒。这是一种用于实验室和医院检测的一次性体外诊断设备。这款包罗万象的套件仅需10分钟即可产生快速、直观的效果。
这是一种定性的横向流动免疫层析法,用于检测人口咽、鼻和鼻咽拭子中的SARSCoV-2抗原。
该盒含有与金纳米颗粒结合的抗SARS-CoV-2/COVID19单克隆抗体,金纳米颗粒与样本中存在的任何SARS-CoV-2抗原结合。抗SARS-CoV-2的单克隆抗体被包裹在硝化纤维素膜上的测试区域,该膜与抗原抗体复合物结合,并由于金纳米颗粒而形成彩色线。盒式磁带上端的控制区域确认测试是否成功。
读数应在C(控制)区域显示1行。根据接触冠状病毒的情况,G(IgG)和M(IgM)区域旁边可能出现紫色线。微弱的线条被视为阳性结果

SARS-CoV-2逆转录定量PCR试剂盒
Abbexa也很高兴向客户提供我们的qPCR套件。
严重急性呼吸综合征冠状病毒2(SARS-CoV-2/COVID19)RT-qPCR试剂盒,用于在单管中高效合成cDNA和实时PCR。
该试剂盒包含一组荧光探针引物,用于区分2019 nCoV/COVID19/SARS-CoV-2和SARS-CoV(bat SARS相关CoV)。SARS-CoV-2 RNA可在FAM通道中检测到,SARS-CoV RNA可在HEX、VIC或JOE通道中检测到(取决于所用设备)。

COVID19 Kits
Catalogue Number Product Name Description
abx365044 Human SARS-CoV-2 Neutralizing Antibody ELISA Kit For the qualitative detection of
SARS-CoV-2/COVID19 Neutralizing Antibodies in
Human serum and plasma.
abx365086 Human SARS-CoV-2 Neutralizing Antibody ELISA Kit For the semi-quantitative detection of
SARS-CoV-2/COVID19 Neutralizing Antibodies in
Human serum and plasma.
abx392294 Human SARS-CoV-2 Nucleocapsid Protein IgG ELISA Kit For the qualitative detection of
SARS-CoV-2/COVID19 Nucleocapsid Protein IgG
antibodies in Human serum and plasma.
abx392295 Human SARS-CoV-2 Nucleocapsid Protein IgM ELISA Kit For the qualitative detection of
SARS-CoV-2/COVID19 Nucleocapsid Protein IgM
antibodies in Human serum and plasma.
abx365028 Human SARS-CoV-2 Spike Protein IgG ELISA Kit For the qualitative detection of
SARS-CoV-2/COVID19 Spike Protein IgG antibodies in Human serum and plasma.
abx365029 Human SARS-CoV-2 Spike Protein IgM ELISA Kit For the qualitative detection of
SARS-CoV-2/COVID19 Spike Protein IgM antibodies in Human serum and plasma.
abx365085 Human SARS-CoV-2
Spike Protein Total Antibody
ELISA Kit
For the qualitative detection of
SARS-CoV-2/COVID19 Spike Protein total antibodies in Human serum and plasma.
abx365030 SARS-CoV-2 Nucleocapsid Protein ELISA Kit For the quantitative detection of
SARS-CoV-2/COVID19 Nucleocapsid Protein in Hu- man serum, plasma and other biological fluids.
abx365031 SARS-CoV-2 Spike Protein S1 RBD ELISA Kit For the quantitative detection of
SARS-CoV-2/COVID19 Spike Protein S1 RBD in Human tissue homogenates, cell lysates, cell culture supernatants, saliva, and other biological fluids.

 

Mutant SARS-CoV-2 Recombinant Proteins
Beta (South Africa) B.1.351 Variant – K417N, E484K and N501Y Mutations
The Beta (B.1.351) variant was first identified in South Africa. It contains the K417N, E484K and N501Y mutations in the spike protein’s receptor-binding domain.
Catalogue Number Product Name Description
abx160085 SARS-CoV-2 S1
Protein RBD (Beta B.1.351 Variant)
Recombinant protein expressed in Insect cells.
Tag: C-terminal His-tag.
abx620004 SARS-CoV-2 Spike Protein RBD
(Beta B.1.351 Variant)
Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.
Gamma (Brazil) P.1 Variant – K417T, E484K and N501Y Mutations
The Gamma (P.1) variant was first identified in Brazil. It contains the K417T, E484K and N501Y mutations in the spike protein’s receptor-binding domain.
Catalogue Number Product Name Description
abx160086 SARS-CoV-2 S1
Protein RBD (Gamma P.1 Variant)
Recombinant protein expressed in Insect cells.
Tag: C-terminal His-tag.
abx620006 SARS-CoV-2 Spike Protein RBD (Gamma P.1 Variant) Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.
Epsilon (California) B.1.429/B.1.427 (CAL.20C) Variant – L452R Mutation
The L452R mutation is present in the B.1.429/B.1.427 (CAL.20C/Epsilon) variants first identified in California, USA.
Catalogue Number Product Name Description
abx160087 SARS-CoV-2 S1
Protein RBD (L452R Mutation)
Recombinant protein expressed in Insect cells.
Tag: C-terminal His-tag.
abx620007 SARS-CoV-2 Spike Protein RBD (L452R Mutation) Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.

 

Mutant SARS-CoV-2 Recombinant Proteins
India B.1.36 (AP) Variant — N450K Mutation
The N450K mutation is present in the B.1.36 variant first identified in Andhra Pradesh, India.
Catalogue Number Product Name Description
abx620011 SARS-CoV-2 Spike Protein RBD (N450K Mutation) Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.
Kappa (India) B.1.617.1 Variant — E484Q and L452R Double-Mutation
The B.1.617 variant was first identified in India. It contains the E484Q and L452R mutations and is therefore widely known as a “double mutation” variant. These mutations have been reported to increase binding to human ACE2 and reduce antibody neutralization of the virus, in comparison with other variants.
Catalogue Number Product Name Description
abx160088 SARS-CoV-2 S1
Protein RBD (B.1.617 Variant)
Recombinant protein expressed in Insect cells.
Tag: His-tag.
abx620009 SARS-CoV-2 Spike Protein RBD (B.1.617 Variant) Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.
Delta (India) B.1.617.2 Variant — L452R and T478K Double-Mutation
The B.1.617.2 (Delta) variant was first identified in India. It contains the L452R and T478K mutations, which appear to increase viral infectivity compared with other variants.
Catalogue Number Product Name Description
abx620012 SARS-CoV-2 Spike Protein RBD
(Delta B.1.617.2 Variant)
Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.

 

Mutant SARS-CoV-2 Recombinant Proteins
Delta Plus B.1.617.2 (AY.1) Variant — K417N, L452R and T478K Mutations
The B.1.617.2.1 (Delta Plus) variant, also known as AY.1, contains the K417N mutation as well as the L452R and T478K mutations in the original B.1.617.2 (Delta) variant. These mutations appear to increase viral infectivity compared with other variants.
Catalogue Number Product Name Description
abx620018 SARS-CoV-2 Spike Protein RBD
(Delta Plus B.1.617.2.1 Variant)
Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.
Other Mutations
The E484K mutation is present in several variants, including those first identified in South Africa and Brazil. This mutation has been reported to reduce antibody neutralization of the virus.
The S477N mutation has been reported to increase binding to human ACE2.
Catalogue Number Product Name Description
abx620005 SARS-CoV-2 Spike Protein RBD (E484K Mutation) Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.
abx620008 SARS-CoV-2 Spike Protein RBD (S477N Mutation) Recombinant protein expressed in Mammalian cells.
Tag: C-terminal His-tag.
SARS-CoV-2 Antibody Pairs
Catalogue Number Product Name Description
abx024239 SARS-CoV-2/COVID19
Nucleocapsid Protein
Antibody
Mouse Monoclonal against SARS-CoV-2/
COVID19 NP (Capture Antibody)
abx024238 SARS-CoV-2/COVID19
Nucleocapsid Protein
Antibody
Mouse Monoclonal against SARS-CoV-2/
COVID19 NP (Detection Antibody)
abx024240 SARS-CoV-2/COVID19 Trimer-
ic Spike 1 Protein Antibody
Mouse Monoclonal against SARS-CoV-2/ COVID19 Trimeric S1 Protein (Capture Antibody)
abx024241 SARS-CoV-2/COVID19 Trimer-
ic Spike 1 Protein Antibody
Mouse Monoclonal against SARS-CoV-2/ COVID-9 Trimeric S1 Protein (Detection Antibody)
abx243136 SARS-CoV-2/COVID19
Spike Glycoprotein RBD Antibody Pair
Contains a recombinant Llama with Human IgG1 Fc capture antibody, and recombinant Mouse with Human IgG1 Fc detection antibody.

 

SARS-CoV-2 IgG / IgM抗体快速检测试剂盒说明书

krishgen SARS-CoV-2 IgG / IgM抗体快速检测试剂盒说明书

SARS-CoV-2 IgG / IgM抗体快速检测试剂盒

SARS-CoV-2(Covid19)是由最近发现的冠状病毒引起的传染病。COVID19 IgG / IgM快速检测(全血/血清/血浆)是一种快速色谱免疫测定法,用于定量测定人全血,血清或血浆中针对COVID19的IgG和IgM抗体。

产品特色

更容易:无需特殊设备,直观的视觉解释。

快速:通过指尖血液快速采样,结果在10-15分钟内。

准确:分别使用IgG和IgM获得的结果。

应用:作为大量潜在可疑患者的筛查工具。

IgG和IgM抗体快速检测试剂盒

KBR010 | GENLISA人源抗SARS-CoV-2(Covid19)IgM快速测试(快速免疫色谱法定性测定血清,血浆和全血中Covid19(SARS-CoV-2))

KBR011 | GENLISA人类抗SARS-CoV-2(Covid19)IgG / IgM快速测试(快速免疫色谱法,用于定性测定血清,血浆和全血中针对Covid-19的IgG / IgM抗体(SARS-CoV-2)。(CE IVD标记)

我们应该如何解释IgM / IgG血清学检测结果?

目前的IgM / IgG血清学检测旨在补充RT-qPCR,以诊断SARS-CoV-2感染。下表显示了同时使用RT-qPCR和IgM / IgG血清学测试对患者进行测试时的临床解释。

表:IgM / IgG血清学检测结果的临床意义
 

 

该表基于最近的研究和临床数据,这些数据涉及对SARS-CoV-2 RNA和抗原,IgM抗体和IgG抗体的调节(图1)以及这些水平变化与初始感染时间,发病时间的相关性。症状和恢复阶段。如下图所示,建议在症状发作后至少3天或感染病毒后7-10天对患者进行血清学检测。

图1:感染后SARS-CoV-2 RNA和抗原,IgM和IgG水平的变化。
 

 

可以理解,RT-qPCR和IgM / IgG血清学测试的结果不一定要一致。这两个测试之间的差异(如果有的话)通常可以追溯到执行测试的感染后时间点。总体而言,尽管RT-qPCR测试可能适合于急性期的SARS-CoV-2病毒检测,但IgM / IgG是慢性期的合适检测。由于通常不知道确切的感染时间,因此将RT-qPCR和IgM / IgG检测结合使用可以提高COVID-19诊断的准确性。

参考:

1.李R,裴S,陈B,宋Y,张T,杨W,萨满J2。大量无证感染可促进冠状病毒(SARS-CoV2)的快速传播。科学。2020年3月16日。pii:eabb3221。

2. Lauer,S.等,2020。根据公开报告的确诊病例,冠状病毒病的潜伏期2019(COVID-19):估计和应用。内科医学年鉴。

3.中华人民共和国国家卫生委员会,新的冠状病毒性肺炎诊断和治疗计划(第7版)。

4.致KK,曾OT,梁WS,谭AR,吴TC,龙DC等。(2020)。口鼻后唾液样品中病毒载量的时间变化和SARS-CoV-2感染期间的血清抗体反应:一项观察性队列研究。柳叶刀感染病。2020年3月23日。pii:S1473-3099(20)30196-1。

 

nanohelix SARS-CoV-2 多重检测简介

 

nanohelix SARS-CoV-2 多重检测简介
[仅供研究使用]

  • SARS-CoV-2 的直接、快速、可靠和多基因检测

  • 直接:适用于纯化的 RNA 和未纯化的样本

  • 快速: 50 分钟 [样品制备 5 分钟 + qRT-PCR 45 分钟/40 个循环]

  • 可靠:针对 SARS-CoV-2(S、ORF8、N)和人类(RNase P)的 4 种目标检测

  • UDG 系统:防止残留污染

产品

货号 产品 尺寸
DFSCV100 DirectFast™ SARS-CoV-2 多重检测 [仅供研究使用] 100 次

描述:


SARS-CoV-2 多重检测

[仅供研究使用]

  • SARS-CoV-2 的直接、快速、可靠和多基因检测

  • 直接:适用于纯化的 RNA 和未纯化的样本

  • 快速: 50 分钟 [样品制备 5 分钟 + qRT-PCR 45 分钟/40 个循环]

  • 可靠:针对 SARS-CoV-2(S、ORF8、N)和人类(RNase P)的 4 种目标检测

  • UDG 系统:防止残留污染

产品

货号 产品 尺寸
DFSCV100 DirectFast™ SARS-CoV-2 多重检测 [仅供研究使用] 100 次
  • 描述

  •  

  •  

DirectFast ™ SARS-CoV-2 多重检测是一种基于探针的实时 RT-PCR 试剂盒,专为 SARS-CoV-2 RNA 的“直接”和“快速”检测而设计。通过裂解缓冲液 (NAExDB) 或加热制备的粗 RNA 样品以及纯化的 RNA 可用作该检测试剂盒的模板,而不会影响灵敏度和准确性。使用此快速试剂盒,反应可在一小时内快速完成实时 RT-PCR 循环(40 个循环需要 45-50 分钟)。多靶点检测( SARS-CoV-2 的ORF8、N、S基因)降低了由病毒 RNA 突变引起的假阴性结果的风险。此外,该检测还安装了不耐热的 UNG(尿嘧啶-N-糖基化酶)和 dUTP 系统,以防止残留污染。


  

图:使用 DirectFast™ SARS-CoV-2 多重检测法灵敏检测 SARS-CoV-2。将 SARS-CoV-2 病毒 RNA 以 10 6 ~ 10 1拷贝/μL的浓度加标到鼻咽拭子集合(在 UTM 中) 。根据本产品的 IFU 从每个加标样品中制备 RNA。每3μL纯化的病毒RNA作为模板用于SARS-CoV-2检测。反应在实时 PCR 仪器 Bio-Rad CFX96 上进行。

 

 

 

 

 

 

 

 

 

 

 

 

 


应用 

  • 直接实时检测 SARS-CoV-2 

 

 

质量控制

功能分析

DirectFast™ SARS-CoV-2 多重检测通过实时 RT-PCR 进行评估,使用 10 倍连续稀释纯化的 SARS-CoV-2 RNA 和 PC(SCV2),并根据协议使用目标特异性引物和水解探针提供。

重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

产品说明书

FAQ

COA

已发表文献

 

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses. The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Several emerging SARS-CoV-2 genomes have been identified including the Omicron, or B.1.1.529, variant. First identified in November 2021 in South Africa, the Omicron variant quickly became the predominant SARS-CoV-2 variant and is considered a variant of concern (VOC). The Omicron variant contains 15 mutations in RBD domain that potentially affect viral fitness and transmissibility. The majority of the mutations are involved in ACE-2 binding and Omicron binds ACE-2 with greater affinity, potentially explaining its increased transmissibility.  

 

产品性质

别名

S protein; Spike glycoprotein; S glycoprotein; COVID-19

Accession

QHO60594.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike S (Omicron B.1.1.529) Trimer Protein is expressed from HEK293 Cells with His tag at the C-terminal. It contains Val16-Pro1213(A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F). Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.

分子量

Approximately 136.70 kDa. Due to glycosylation, the protein migrates to 140-180 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE.

活性

ELISA DataImmobilized SARS-COV-2 Spike S (Omicron B.1.1.529) Trimer, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 16.7ng/ml determined by ELISA.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

 

冰袋运输-20-80存,一年有效期

复溶后,20 -80°C,在未开封状态下保存 3-6 个月复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装存,避免反复冻融

 

注意事项

1. 避免反复冻融。

2. 为了您的安全和健康,请穿实验服并戴一次性手套操作。

3. 本产品仅作科研用途!

 

产品数据
重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

HB220811

重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

暂无内容

重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

暂无内容

 

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses. The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Several emerging SARS-CoV-2 genomes have been identified including the Omicron, or B.1.1.529, variant. First identified in November 2021 in South Africa, the Omicron variant quickly became the predominant SARS-CoV-2 variant and is considered a variant of concern (VOC). The Omicron variant contains 15 mutations in RBD domain that potentially affect viral fitness and transmissibility. The majority of the mutations are involved in ACE-2 binding and Omicron binds ACE-2 with greater affinity, potentially explaining its increased transmissibility.  

 

产品性质

别名

S protein; Spike glycoprotein; S glycoprotein; COVID-19

Accession

QHO60594.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike S (Omicron B.1.1.529) Trimer Protein is expressed from HEK293 Cells with His tag at the C-terminal. It contains Val16-Pro1213(A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F). Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.

分子量

Approximately 136.70 kDa. Due to glycosylation, the protein migrates to 140-180 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE.

活性

ELISA DataImmobilized SARS-COV-2 Spike S (Omicron B.1.1.529) Trimer, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 16.7ng/ml determined by ELISA.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

 

冰袋运输-20-80存,一年有效期

复溶后,20 -80°C,在未开封状态下保存 3-6 个月复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装存,避免反复冻融

 

注意事项

1. 避免反复冻融。

2. 为了您的安全和健康,请穿实验服并戴一次性手套操作。

3. 本产品仅作科研用途!

 

产品数据
重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

HB220811

重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

暂无内容

重组SARS-COV-2刺突S(B.1.1.529/Omicron)三聚体(His标签)

暂无内容

重组SARS-COV-2刺突S1-NTD(His-Flag标签)

重组SARS-COV-2刺突S1-NTD(His-Flag标签)

产品说明书

FAQ

COA

已发表文献

 

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS‑CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2. In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor, while the S2 subunit is involved with cell fusion. The S1 subunit can be further divided into an N-terminal domain (NTD) and a receptor binding domain (RBD). The SARS-CoV-2 NTD shares 50% and 20% amino acid (aa) sequence identity with the NTD of SARS-CoV-1 and MERS-CoV, respectively. The NTD is reported to bind L-SIGN and DC-SIGN in cells that don't express the ACE-2 receptor. Despite being heavily glycosylated, the NTD is capable of eliciting an immune response to produce potent neutralization antibodies, although at a reduced level than the ones targeting the RBD. Three immunogenic regions have been identified in the NTD: aa 14-20, aa 140-158, and aa 245-264. Antibody cocktails targeting both NTD and RBD could provide better protection against SARS-CoV-2 infection.

 

产品性质

别名

S1 protein NTD,Spike glycoprotein Subunit1 NTD,S glycoprotein Subunit1 NTD,Spike protein S1 NTD

Accession

QHD43416.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike S1 NTD Protein is expressed from HEK293 Cells with His tag and Flag tag at the C-terminal. It contains Val16-Ser305.

分子量

Approximately 35 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

 

冰袋运输-20-80存,一年有效期

复溶后,20 -80°C,在未开封状态下保存 3-6 个月复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装存,避免反复冻融

 

注意事项

1. 避免反复冻融。

2. 为了您的安全和健康,请穿实验服并戴一次性手套操作。

3. 本产品仅作科研用途!

 

产品数据

重组SARS-COV-2刺突S1-NTD(His-Flag标签)
 

HB220811

重组SARS-COV-2刺突S1-NTD(His-Flag标签)

暂无内容

重组SARS-COV-2刺突S1-NTD(His-Flag标签)

暂无内容

 

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS‑CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2. In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor, while the S2 subunit is involved with cell fusion. The S1 subunit can be further divided into an N-terminal domain (NTD) and a receptor binding domain (RBD). The SARS-CoV-2 NTD shares 50% and 20% amino acid (aa) sequence identity with the NTD of SARS-CoV-1 and MERS-CoV, respectively. The NTD is reported to bind L-SIGN and DC-SIGN in cells that don't express the ACE-2 receptor. Despite being heavily glycosylated, the NTD is capable of eliciting an immune response to produce potent neutralization antibodies, although at a reduced level than the ones targeting the RBD. Three immunogenic regions have been identified in the NTD: aa 14-20, aa 140-158, and aa 245-264. Antibody cocktails targeting both NTD and RBD could provide better protection against SARS-CoV-2 infection.

 

产品性质

别名

S1 protein NTD,Spike glycoprotein Subunit1 NTD,S glycoprotein Subunit1 NTD,Spike protein S1 NTD

Accession

QHD43416.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike S1 NTD Protein is expressed from HEK293 Cells with His tag and Flag tag at the C-terminal. It contains Val16-Ser305.

分子量

Approximately 35 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

 

冰袋运输-20-80存,一年有效期

复溶后,20 -80°C,在未开封状态下保存 3-6 个月复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装存,避免反复冻融

 

注意事项

1. 避免反复冻融。

2. 为了您的安全和健康,请穿实验服并戴一次性手套操作。

3. 本产品仅作科研用途!

 

产品数据

重组SARS-COV-2刺突S1-NTD(His-Flag标签)
 

HB220811

重组SARS-COV-2刺突S1-NTD(His-Flag标签)

暂无内容

重组SARS-COV-2刺突S1-NTD(His-Flag标签)

暂无内容

IPA确认发现了针对SARS-CoV-2的完*有效的中和抗体

 

IPA确认发现了针对SARS-CoV-2的完*有效的中和抗体

IPA宣布发现来自人类和骆驼(VHH)的功能抗体,这些抗体已使用IPA噬菌体展示技术鉴定。

维多利亚,2020年6月29 日 –IMMUNOPRECISE ANTIBODIES LTD。(“公司”或“ IPA”)(TSX VENTURE:IPA)(OTCQB:IPATF)(FSE:TQB2),是提供方位服务的治疗性抗体发现和开发的经验丰富的,今天宣布了对众多潜在候选抗体的鉴定具有强效的体外中和活性,可用于进一步测试,并可能包含在公司的PolyTopeTM mAb疗法中,以对抗COVID19大流行。

2020 年3月12 日,ImmunoPrecise宣布了目前正在开展的一些临床前计划,以协助抗击SARS-CoV-2。今天的公告更新了该公司在开发PolyTope™mAb疗法方面的进展,该疗法旨在治疗重症患者,并保护高危人群,例如暴露于病毒,一线工人,老年人和免疫功能低下的人群。

ImmunoPrecise部署了几个专有的发现平台,这些平台利用了人类,美洲驼,兔和Ligand Pharmaceutical(NASDAQ:LGND)的OmniAb®基因工程大鼠产生人类抗体的免疫系统。今天宣布的中和抗体是从人类和美洲驼战役中分析的前300种抗体进行功能筛选的结果。该公司表示,对兔子和OmniAb大鼠运动中剩余的1300种先导抗体的功能分析是独立进行的,他们预计不久的将来会从这些其他程序中发布初步的功能数据筛选。

IPA执行官兼总裁Jennifer Bath博士说:“在我们的初步研究中,这个关键时刻到达了许多*的功能性治疗候选药物,这表明IPA的抗COVID19计划具有广泛的科学范围。” “针对COVID19的有效鸡尾酒疗法,针对该病毒的多个表位,可以证明以有效和持久的方式对抗这种流行病至关重要。”

该公司的科学方法已导致了多种候选先导抗体,并且迄今为止,已经产生了针对多种表位的许多强力中和抗体,支持了该公司的目标,即使在SARS-CoV-2继续发展的情况下,也能保持疗效。 。为了进一步支持公司强大的科学方法,IPA正在准备测试这些先导抗体是否针对其他有文件证明的病毒突变株。

公司预计临床前研究将于2020年夏季开始。

ImmunoPrecise执行官Jennifer Bath博士已审查并批准了此新闻稿的科学披露。

在临床试验中对人类使用治疗药物需要获得政府监管机构的批准,例如,公司未明示或暗示声称其产品具有消除,治愈或含有COVID19(或SARS-CoV)的能力-2)。

关于ImmunoPrecise抗体有限公司

ImmunoPrecise是一家提供方位服务的治疗性抗体发现合同研究组织,为制药客户在较短的时间内为其提供与物种无关的,多格式,特征化和工程化的人类单克隆抗体

 

 

前瞻性信息

本新闻稿包含的声明在一定程度上不是对历史事实的叙述,可能构成适用的加拿大证券法所定义的“前瞻性声明”。公司使用诸如“可能”,“将要”,“可能”,“将要”,“可能”,“期望”,“相信”,“打算”等词语来表述前瞻性陈述。任何此类前瞻性陈述均基于ImmunoPrecise的经验和对历史趋势,当前状况和预期未来发展的理解,并基于这些假设和分析。但是,实际结果和发展是否符合ImmunoPrecise的期望和预测会受到许多风险,假设和不确定性的影响。许多因素可能导致ImmunoPrecise的实际结果与本新闻稿中包含的前瞻性陈述所表达或暗示的结果有实质性差异。这些因素包括,除其他因素外,ImmunoPrecise可能无法成功开发用于预防,治疗或诊断SARS-CoV-2的任何疫苗,疗法或诊断试剂盒,IPA的实际收入和收益低于因COVID19大流行而产生的预期潜在负面影响,例如监管审查延迟,制造和临床试验,供应链中断和经济中断,以及ImmunoPrecise年度管理讨论和分析中描述的那些风险和不确定性。截至2020年1月31日的上一季度,此处包含的“前瞻性陈述”仅是截至本新闻发布之日为止,除非适用法律要求,否则ImmunoPrecise不承担由于新信息,未来事件或其他原因而公开更新或修改此类信息的义务。除此以外。

 

源自u-proteinexpress

重组SARS-COV-2刺突RBD蛋白(Omicron BF.7/BA.4.6)His标签

重组SARS-COV-2刺突RBD蛋白(Omicron BF.7/BA.4.6)His标签

产品说明书

FAQ

COA

已发表文献

 

Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) . The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 . The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2).

 

产品信息

别名

S protein RBD; S glycoprotein RBD; Spike protein RBD

Accession

QHD43416.1

表达区间及表达系统

Recombinant SARS-CoV-2 Spike RBD (Omicron BF.7/BA.4.6) Protein is expressed from Expi293 with His tag at the C-terminal. It contains Arg319-Phe541(G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H).

分子量

Approximately 25.99 kDa. Due to glycosylation, the protein migrates to 35-43 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

活性

ELISA DataImmobilized SARS-CoV-2 Spike RBD (Omicron BF.7/BA.4.6) , His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 15.8ng/ml determined by ELISA.

内毒素

< 1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

储存条件

The product should be stored at -25~-15℃.

1 month, 2 ~8 °C under sterile conditions after reconstitution.

3 months, -25~-15℃ °C under sterile conditions after reconstitution.

Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

 

注意事项

1.Please operate with lab coats and disposable glovesfor your safety

2.This product is for research use only.

 

重组SARS-COV-2刺突RBD蛋白(Omicron BF.7/BA.4.6)His标签

暂无内容

重组SARS-COV-2刺突RBD蛋白(Omicron BF.7/BA.4.6)His标签

暂无内容

 

Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) . The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 . The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2).

 

产品信息

别名

S protein RBD; S glycoprotein RBD; Spike protein RBD

Accession

QHD43416.1

表达区间及表达系统

Recombinant SARS-CoV-2 Spike RBD (Omicron BF.7/BA.4.6) Protein is expressed from Expi293 with His tag at the C-terminal. It contains Arg319-Phe541(G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H).

分子量

Approximately 25.99 kDa. Due to glycosylation, the protein migrates to 35-43 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

活性

ELISA DataImmobilized SARS-CoV-2 Spike RBD (Omicron BF.7/BA.4.6) , His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 15.8ng/ml determined by ELISA.

内毒素

< 1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

储存条件

The product should be stored at -25~-15℃.

1 month, 2 ~8 °C under sterile conditions after reconstitution.

3 months, -25~-15℃ °C under sterile conditions after reconstitution.

Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

 

注意事项

1.Please operate with lab coats and disposable glovesfor your safety

2.This product is for research use only.

 

重组SARS-COV-2刺突RBD蛋白(Omicron BF.7/BA.4.6)His标签

暂无内容

重组SARS-COV-2刺突RBD蛋白(Omicron BF.7/BA.4.6)His标签

暂无内容

重组SARS-COV-2刺突S1(奥密克戎)(His标签)

重组SARS-COV-2刺突S1(奥密克戎)(His标签)

产品说明书

FAQ

COA

已发表文献

 

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses. The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Several emerging SARS-CoV-2 genomes have been identified including the Omicron, or B.1.1.529, variant. First identified in November 2021 in South Africa, the Omicron variant quickly became the predominant SARS-CoV-2 variant and is considered a variant of concern (VOC). The Omicron variant contains 15 mutations in RBD domain that potentially affect viral fitness and transmissibility. The majority of the mutations are involved in ACE-2 binding and Omicron binds ACE-2 with greater affinity, potentially explaining its increased transmissibility. Several of these mutations are also identified in facilitating immune escape and reducing neutralization activity to several monoclonal antibodies.

 

产品性质

别名

S1 protein; Spike protein S1; Spike,S1 protein; S glycoprotein Subunit1

Accession

QHO60594.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike S1 (Omicron B.1.1.529) Protein is expressed from HEK293 Cells with His tag at the C-terminal. It contains Gln14-Arg683(A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H).

分子量

Approximately 76.38 kDa. Due to glycosylation, the protein migrates to 130-145 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

活性

ELISA DataImmobilized Human ACE2, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for SARS-COV-2 Spike S1 (Omicron B.1.1.529) , His Tag with the EC50 of 0.8μg/ml determined by ELISA.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

 

冰袋运输-20-80存,一年有效期

复溶后,20 -80°C,在未开封状态下保存 3-6 个月复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装存,避免反复冻融

 

注意事项

1. 避免反复冻融。

2. 为了您的安全和健康,请穿实验服并戴一次性手套操作。

3. 本产品仅作科研用途!

 

产品数据

重组SARS-COV-2刺突S1(奥密克戎)(His标签)
重组SARS-COV-2刺突S1(奥密克戎)(His标签)

 

HB220811

重组SARS-COV-2刺突S1(奥密克戎)(His标签)

暂无内容

重组SARS-COV-2刺突S1(奥密克戎)(His标签)

暂无内容

 

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses. The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Several emerging SARS-CoV-2 genomes have been identified including the Omicron, or B.1.1.529, variant. First identified in November 2021 in South Africa, the Omicron variant quickly became the predominant SARS-CoV-2 variant and is considered a variant of concern (VOC). The Omicron variant contains 15 mutations in RBD domain that potentially affect viral fitness and transmissibility. The majority of the mutations are involved in ACE-2 binding and Omicron binds ACE-2 with greater affinity, potentially explaining its increased transmissibility. Several of these mutations are also identified in facilitating immune escape and reducing neutralization activity to several monoclonal antibodies.

 

产品性质

别名

S1 protein; Spike protein S1; Spike,S1 protein; S glycoprotein Subunit1

Accession

QHO60594.1

表达区间及表达系统

Recombinant SARS-COV-2 Spike S1 (Omicron B.1.1.529) Protein is expressed from HEK293 Cells with His tag at the C-terminal. It contains Gln14-Arg683(A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H).

分子量

Approximately 76.38 kDa. Due to glycosylation, the protein migrates to 130-145 kDa based on Tris-Bis PAGE result.

纯度

> 95% as determined by SDS-PAGE and HPLC.

活性

ELISA DataImmobilized Human ACE2, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for SARS-COV-2 Spike S1 (Omicron B.1.1.529) , His Tag with the EC50 of 0.8μg/ml determined by ELISA.

内毒素

1.0 EU per 1μg of the protein by the LAL method.

制剂

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

复溶

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

 

运输与保存方法

 

冰袋运输-20-80存,一年有效期

复溶后,20 -80°C,在未开封状态下保存 3-6 个月复溶后,2-8°C 保存 2-7 天。

建议第一次使用时分装存,避免反复冻融

 

注意事项

1. 避免反复冻融。

2. 为了您的安全和健康,请穿实验服并戴一次性手套操作。

3. 本产品仅作科研用途!

 

产品数据

重组SARS-COV-2刺突S1(奥密克戎)(His标签)
重组SARS-COV-2刺突S1(奥密克戎)(His标签)

 

HB220811

重组SARS-COV-2刺突S1(奥密克戎)(His标签)

暂无内容

重组SARS-COV-2刺突S1(奥密克戎)(His标签)

暂无内容